Anxiety and depression symptoms and response to methylphenidate in children with attention-deficit hyperactivity disorder and tic disorder

被引:43
作者
Gadow, KD
Nolan, EE
Sverd, J
Sprafkin, J
Schwartz, J
机构
[1] SUNY Stony Brook, Dept Psychiat & Behav Sci, Stony Brook, NY 11794 USA
[2] Sagamore Childrens Psychiat Ctr, Dix Hills, NY USA
关键词
D O I
10.1097/00004714-200206000-00007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This study examined response to methylphenidate in children with attention-deficit/hyperactivity disorder (ADHD) and chronic multiple tic disorder. The primary goal was to determine if children with anxiety or depression symptoms showed a less favorable response to treatment. Subjects were 38 prepubertal children who participated in an 8-week, double-blind, placebo-controlled, methylphenidate crossover evaluation. Treatment effects were assessed with direct observations of child behavior in public school and clinic settings; rating scales completed by parents, teachers, and clinicians; and laboratory analogue tasks. There was little evidence (group data) that children with anxiety or depression symptoms responded in a clinically different manner to methylphenidate than youngsters who did not exhibit these symptoms, particularly in school observations of the core features of ADHD. Seeming differences between children with and without comorbid anxiety or depression symptoms and drug response are likely explained by differences in pretreatment levels of negativistic behaviors (i.e., symptoms of oppositional defiant disorder or conduct disorder). Methylphenidate appears to be effective for the management of ADHD behaviors in children with mild to moderate anxiety or depression symptoms; nevertheless, much research remains to be performed in this area.
引用
收藏
页码:267 / 274
页数:8
相关论文
共 50 条
  • [21] Population pharmacokinetics of methylphenidate in children with attention-deficit hyperactivity disorder
    Shader, RI
    Harmatz, JS
    Oesterheld, JR
    Parmelee, DX
    Sallee, FR
    Greenblatt, DJ
    JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 39 (08) : 775 - 785
  • [23] Pharmacogenetics of methylphenidate response and tolerability in attention-deficit/hyperactivity disorder
    Pagerols, M.
    Richarte, V.
    Sanchez-Mora, C.
    Garcia-Martinez, I.
    Corrales, M.
    Corominas, M.
    Cormand, B.
    Casas, M.
    Ribases, M.
    Ramos-Quiroga, J. A.
    PHARMACOGENOMICS JOURNAL, 2017, 17 (01) : 98 - 104
  • [24] METHYLPHENIDATE AND INTERPERSONAL RELATIONSHIPS OF CHILDREN WITH ATTENTION-DEFICIT HYPERACTIVITY DISORDER
    MINO, Y
    OHARA, H
    JAPANESE JOURNAL OF PSYCHIATRY AND NEUROLOGY, 1991, 45 (01): : 45 - 51
  • [25] Methylphenidate Transdermal SystemIn Attention-Deficit Hyperactivity Disorder in Children
    Vanessa R. Anderson
    Lesley J. Scott
    Drugs, 2006, 66 : 1117 - 1126
  • [26] Methylphenidate in the treatment of children and adolescents with bipolar disorder and Attention-Deficit/Hyperactivity disorder
    Findling, Robert L.
    Short, Elizabeth J.
    McNamara, Nora K.
    Demeter, Christine A.
    Stansbrey, Robert J.
    Gracious, Barbara L.
    Whipkey, Resaca
    Manos, Michael J.
    Calabrese, Joseph R.
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2007, 46 (11) : 1445 - 1453
  • [27] Use of methylphenidate in attention-deficit hyperactivity disorder
    Jean-Tron, Maria G.
    Marquez-Gonzalez, Horacio
    Barragan-Perez, Eduardo
    Barajas-Nava, Leticia A.
    BOLETIN MEDICO DEL HOSPITAL INFANTIL DE MEXICO, 2020, 77 (01): : 42 - 45
  • [28] Pharmacogenetics of methylphenidate response and tolerability in attention-deficit/hyperactivity disorder
    M Pagerols
    V Richarte
    C Sánchez-Mora
    I Garcia-Martínez
    M Corrales
    M Corominas
    B Cormand
    M Casas
    M Ribasés
    J A Ramos-Quiroga
    The Pharmacogenomics Journal, 2017, 17 : 98 - 104